New potent and selective tankyrase inhibitors for the treatment of disease or conditions associated with Wnt signalling e.g. colon cancer, prostate cancer, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and type-1/type-2 diabetes.
This is the latest version of this item.
Nathubhai, Amit, Threadgill, M D (2016) New potent and selective tankyrase inhibitors for the treatment of disease or conditions associated with Wnt signalling e.g. colon cancer, prostate cancer, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and type-1/type-2 diabetes. WO2017-GB52624.
| Item Type: | Patents |
|---|
Full text not available from this repository.
More Information
| Depositing User: Amit Nathubhai |
Identifiers
| Item ID: 9804 |
| Identification Number: WO2017-GB52624 |
| URI: http://sure.sunderland.ac.uk/id/eprint/9804 | Official URL: https://worldwide.espacenet.com/publicationDetails... |
Users with ORCIDS
Catalogue record
| Date Deposited: 10 Aug 2018 13:52 |
| Last Modified: 18 Dec 2019 16:07 |
| Author: | Amit Nathubhai |
| Author: | M.D. Threadgill |
University Divisions
Faculty of Health Sciences and WellbeingFaculty of Health Sciences and Wellbeing > School of Pharmacy and Pharmaceutical Sciences
Subjects
Sciences > ChemistryActions (login required)
 |
View Item (Repository Staff Only) |
Available Versions of this Item
-
Use of new and known pyridine or pyrimidine compounds, for the treatment of a disease or condition associated with tankyrase, e.g. cancer selected from e.g. breast, colon, stomach, and liver. (deposited 10 Aug 2018 13:49)
- New potent and selective tankyrase inhibitors for the treatment of disease or conditions associated with Wnt signalling e.g. colon cancer, prostate cancer, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and type-1/type-2 diabetes. (deposited 10 Aug 2018 13:52) [Currently Displayed]
